Todd Busman
Impact in
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
- Hematology top 2%
- Acute Myeloid Leukemia Research
Papers in
- Genetics 21
- Chronic Lymphocytic Leukemia Research 21
-
- Advanced Breast Cancer Therapies 7
- Lung Cancer Treatments and Mutations 5
- Co-authors
- Rod Humerickhouse (20 shared papers)Sari H. Enschede (17 shared papers)Hao Xiong (9 shared papers)Andrew Krivoshik (12 shared papers)Yue Cui (5 shared papers)Yi‐Lin Chiu (5 shared papers)Evelyn McKeegan (4 shared papers)William G. Wierda (15 shared papers)
- Journals
- Blood (14 papers)Journal of Clinical Oncology (8 papers)Current Medical Research and Opinion (7 papers)Clinical Therapeutics (3 papers)Investigational New Drugs (2 papers)
- Partner nations
- United StatesAustraliaUnited Kingdom
In The Last Decade
Todd Busman
42 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 92
- Genetics 681
- Hematology 459
- Pathology and Forensic Medicine 514
- Oncology 655
- Molecular Biology 1.5k
Countries citing papers authored by Todd Busman
This map shows the geographic impact of Todd Busman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd Busman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd Busman more than expected).
Fields of papers citing papers by Todd Busman
This network shows the impact of papers produced by Todd Busman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd Busman. The network helps show where Todd Busman may publish in the future.
Co-authors
The 25 scholars most cited alongside Todd Busman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity Hit paper breakdown → | 2010 | 663 |
| 2 | Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease Hit paper breakdown → | 2011 | 632 |
| 3 | 2011 | 462 | |
| 4 | 2018 | 113 | |
| 5 | 2014 | 59 | |
| 6 | 2014 | 50 | |
| 7 | 2015 | 50 | |
| 8 | 2014 | 46 | |
| 9 | 2002 | 43 | |
| 10 | 2013 | 42 | |
| 11 | 2006 | 32 | |
| 12 | 2012 | 28 | |
| 13 | 2015 | 26 | |
| 14 | 2006 | 26 | |
| 15 | 2015 | 26 | |
| 16 | 2002 | 23 | |
| 17 | 2008 | 23 | |
| 18 | 2013 | 20 | |
| 19 | 2005 | 20 | |
| 20 | 2021 | 20 |
About Todd Busman
Todd Busman is a scholar working on Genetics, Pulmonary and Respiratory Medicine, Molecular Biology, Oncology and Public Health, Environmental and Occupational Health, having authored 42 papers that have together received 2.6k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (21 papers), Pneumonia and Respiratory Infections (10 papers), Acute Lymphoblastic Leukemia research (7 papers), Lymphoma Diagnosis and Treatment (7 papers), Advanced Breast Cancer Therapies (7 papers), Cancer therapeutics and mechanisms (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Cell death mechanisms and regulation (5 papers). The work is most often cited by research in Genetics (681 citations), Hematology (459 citations), Pathology and Forensic Medicine (514 citations), Oncology (655 citations) and Molecular Biology (1.5k citations). Todd Busman has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Rod Humerickhouse, Sari H. Enschede, Hao Xiong, Andrew Krivoshik, Yue Cui, Yi‐Lin Chiu, Evelyn McKeegan, William G. Wierda, John F. Seymour and Andrew W. Roberts. Their work appears in journals such as Blood, Journal of Clinical Oncology, Current Medical Research and Opinion, Clinical Therapeutics and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.